[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 33 of about 33
1. Assin R, Baldi A, Citro G, Spugnini EP: Prostate as sole unusual recurrence site of lymphoma in a dog. In Vivo; 2008 Nov-Dec;22(6):755-7
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate as sole unusual recurrence site of lymphoma in a dog.
  • The dog had an intestinal lymphoma treated three years before with chemotherapy.
  • Cytological examination of the fine-needle aspirate from the prostate yielded a diagnosis of lymphoma.
  • The diagnosis was confirmed by histopathological examination.
  • The dog was treated with multi-drug chemotherapy and achieved a complete remission.
  • The dog remained in complete remission for one year from the re-institution of chemotherapy before dying of recurrence.
  • Lymphoma rarely invades the prostate in the dog.
  • To the best of our knowledge this is the first report of prostatic recurrence of lymphoma in a canine patient originally affected by intestinal lymphoma and treated with chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dog Diseases / pathology. Lymphoma / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Animals. Dogs. Male. Recurrence. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19181002.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


2. Feng L, Zhang G, Hu Z, Zou Y, Chen F, Zhang G, Tang L: Diagnosis and treatment of 81 patients with primary gastrointestinal lymphoma. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Jul;34(7):582-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and treatment of 81 patients with primary gastrointestinal lymphoma.
  • OBJECTIVE: To analyze the status quo of the diagnosis and treatments of primary gastrointestinal lymphoma (PGIL) in order to improve it.
  • METHODS: Eighty-one patients with PGIL were analyzed retrospectively including clinical manifestations, endoscopic features, pathological features, HP infection, treatment, and prognosis.
  • RESULTS: The age of patients with gastric lymphoma was (52.84+/-15.33) years.
  • The age of patients with intestinal lymphoma was (42.09+/-15.28) years.
  • Endoscopic appearances were as follows: tumor type (67.7%), ulcer type (27.7%), and diffuse type (4.6%).
  • Clinical diagnosis rate and endoscopic biopsy confirmation rate were 30.9% and 73.8%.
  • MALT lymphoma accounted for 61.7% of the patients.
  • HP detection rate was 39.5% and positive rate was 37.5%.
  • A total of 69 patients received surgeries: 3 had preoperative chemotherapy, and 34 had postoperative chemotherapy.
  • Twelve patients had non-surgical treatment, 6 patients of whom had simple chemotherapy and HP eradication therapy, and the other 6 gave up during the treatment.
  • There was no significant difference in the survival rate of Stage I-II patients in the surgery alone group, surgery plus chemotherapy group, and chemotherapy and HP eradication therapy group(P>0.05).
  • Multi-site biopsy or repeated biopsies and immunohistochemical methods can be used to raise the pathological diagnosis rate.
  • Chemotherapy and HP eradication are recommended.
  • [MeSH-major] Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Neoplasms / therapy. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Combined Modality Therapy. Endoscopy, Gastrointestinal. Female. Humans. Male. Middle Aged. Retrospective Studies. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19648667.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


3. Landolsi A, Chabchoub I, Limem S, Gharbi O, Chaafai R, Hochlef M, Fatma LB, Trimech M, Krifa A, Ajmi S, Mokni M, Hadj Hmida MB, Ahmed SB: [Primary digestive tract lymphoma in central region of Tunisia: anatomoclinical study and therapeutic results about 153 cases]. Bull Cancer; 2010 Apr;97(4):435-43

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary digestive tract lymphoma in central region of Tunisia: anatomoclinical study and therapeutic results about 153 cases].
  • [Transliterated title] Les lymphomes primitifs du tube digestif (LPTD) dans le centre tunisien: étude anatomoclinique et résultats thérapeutiques à propos de 153 cas.
  • Primary gastro-intestinal lymphoma (PGIL) is the most common type of extra-nodal non Hodgkin's lymphoma.
  • There is no consensus regarding the role of surgery and chemotherapy in the therapeutic approach.
  • In our country epidemiology of the disease is unknown with IPSID being the most frequent type.
  • We report anatomo-clinical features and prognostic factors of PGIL and compare intestinal to gastric forms in our region.
  • Tumor sites were gastric (67%), intestinal (26%) and gastrointestinal (7%).
  • Performance status (PS) < 2 was seen in 80% of patients, high grade lymphoma in 70.5% of cases and B phenotype was noted in 85%.
  • MALT lymphoma accounts for 50% of cases, and IPSID for only 5% of PGIL.
  • About 47.5% of cases were stage IE, 138 patients had chemotherapy with an objective response rate of 77%.
  • Only 46% of patients had surgery (14 for surgical complication, 6 for residual tumor after chemotherapy and 22 to have histological diagnosis).
  • In high grade lymphoma patients favorable prognostic factors for OS included young age < or = 60 years, PS < 2, normal serum LDH, hemoglobin > 12 g/dL, B phenotype, localised stage (IE-IIE1), anthracycline-based chemotherapy regimen, achieving complete or partial response to induction chemotherapy and no relapse.
  • In low-grade lymphoma patients, none of these factors had a significant correlation with OS: age < or = 60 years, PS < 2, stage (IE-IIE1), response to induction chemotherapy, relapse.
  • Compared to gastric lymphomas, intestinal cases occurred at a younger age, frequently with diarrhoea, weight loss, and occlusion.
  • We conclude that stomach is the main site of PGIL in our region, intestinal lymphoma is less frequent and IPSID has become rare.
  • Recent progress in chemotherapy has allowed good therapeutic results with a conservative approach.
  • Surgery may be performed in case of emergency or for residual lesions after medical treatment.
  • [MeSH-major] Gastrointestinal Neoplasms. Lymphoma, Non-Hodgkin
  • [MeSH-minor] Abdominal Pain / etiology. Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diarrhea / etiology. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Tunisia. Vomiting / etiology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20395189.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


Advertisement
4. Watanabe N, Sugimoto N, Matsushita A, Maeda A, Nagai K, Hanioka K, Takahashi T: Association of intestinal malignant lymphoma and ulcerative colitis. Intern Med; 2003 Dec;42(12):1183-7
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of intestinal malignant lymphoma and ulcerative colitis.
  • A 42-year-old woman with refractory ulcerative colitis (UC) developed ascites, pleural effusion, pretibial edema and severe anemia.
  • Colonofiberscopic examination showed a bulky submucosal tumor in the sigmoid colon, which was histologically diagnosed as malignant lymphoma (diffuse large, B cell type).
  • The lymphoma was resistant to chemotherapy.
  • Although the association of intestinal lymphoma with UC is rare, lymphoma should be taken into consideration when the clinical course of UC is atypical or when UC is refractory to therapy.
  • [MeSH-major] Colitis, Ulcerative / complications. Lymphoma / complications. Sigmoid Neoplasms / complications
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Colonoscopy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Fatal Outcome. Female. Humans. Ifosfamide / therapeutic use. Methotrexate / therapeutic use. Peripheral Blood Stem Cell Transplantation. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14714955.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate; CAMBO-VIP protocol
  •  go-up   go-down


5. Giri K, Sudar C, Arya M, Haber G, Chandra P: Diagnosis of marginal cell lymphoma of small intestine by double balloon enteroscopy. South Med J; 2008 May;101(5):561-4
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of marginal cell lymphoma of small intestine by double balloon enteroscopy.
  • A 65-year-old woman with a medical history of diabetes mellitus type 2, hypertension, an old cerebrovascular accident, and seizure disorder presented to the emergency room with lower abdominal pain of 4 weeks duration.
  • A computed tomography scan of her abdomen with oral and intravenous contrast showed significantly thickened small bowel loops with subjacent lymphadenopathy.
  • The biopsy showed marginal cell lymphoma.
  • The patient is presently undergoing chemotherapy.
  • For the first time, it provides the means to endoscopically investigate and treat disorders of the small intestine that have previously been inaccessible to conventional endoscopy.
  • [MeSH-major] Endoscopy, Gastrointestinal / methods. Jejunal Neoplasms / diagnosis. Lymphoma / diagnosis
  • [MeSH-minor] Abdominal Pain / etiology. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Capsule Endoscopes. Female. Humans. Immunohistochemistry. Lymph Nodes / radiography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18414178.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Nakamura S, Matsumoto T, Iida M, Yao T, Tsuneyoshi M: Primary gastrointestinal lymphoma in Japan: a clinicopathologic analysis of 455 patients with special reference to its time trends. Cancer; 2003 May 15;97(10):2462-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastrointestinal lymphoma in Japan: a clinicopathologic analysis of 455 patients with special reference to its time trends.
  • BACKGROUND: An optimal treatment modality for patients with primary gastrointestinal lymphoma has not yet been established.
  • This study aimed to elucidate the clinicopathologic features of this disease and the influence of therapeutic modalities on the prognosis in Japanese patients METHODS: The clinicopathologic features of 455 patients with primary gastrointestinal lymphoma were investigated retrospectively regarding treatment modalities and time trends.
  • RESULTS: This study comprised 342 patients (75%) with gastric lymphoma, 96 patients (22%) with intestinal lymphoma, and 17 patients (4%) with both gastric and intestinal lymphoma.
  • Two hundred thirty-one (51%) patients were classified as having low-grade B-cell lymphoma including 200 marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) type, 185 (41%) patients were classified as having high-grade B-cell lymphoma including 76 diffuse large cell lymphoma plus MALT lymphoma, and 39 (9%) patients were classified as having T-cell lymphoma.
  • The frequency of nonsurgical treatment, including Helicobacter pylori eradication, chemotherapy, and radiation, increased during the latest decade.
  • Patients who received nonsurgical treatment showed a better overall survival than those treated by surgery, but event-free survival did not differ between two groups.
  • Mucosa-associated lymphoid tissue-derived lymphoma was also an independent prognostic factor for event-free survival, but not for overall survival.
  • CONCLUSIONS: Nonsurgical treatment may be an optimal therapeutic modality for patients with primary gastrointestinal lymphoma.
  • [MeSH-major] Gastrointestinal Neoplasms / epidemiology. Gastrointestinal Neoplasms / therapy. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Japan / epidemiology. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11415
  • (PMID = 12733145.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Oertel SH, Papp-Váry M, Anagnostopoulos I, Hummel MW, Jonas S, Riess HB: Salvage chemotherapy for refractory or relapsed post-transplant lymphoproliferative disorder in patients after solid organ transplantation with a combination of carboplatin and etoposide. Br J Haematol; 2003 Dec;123(5):830-5
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy for refractory or relapsed post-transplant lymphoproliferative disorder in patients after solid organ transplantation with a combination of carboplatin and etoposide.
  • This pilot study assessed the feasibility and efficacy of salvage chemotherapy (carboplatin and etoposide;.
  • CE) supported by granulocyte colony-stimulating factor (GCSF) in patients with refractory or relapsed post-transplant lymphoproliferative disorder (PTLD) following solid organ transplantation.
  • Salvage chemotherapy consisted of carboplatin [area under the curve (AUC) 4], on day 1, etoposide (120 mg/m2), on days 1-3 and GCSF (5 microg/kg) starting on day 5.
  • This therapeutic regimen was planned to be repeated every 21 d.
  • Two patients experienced early deaths, after the first and third cycles of chemotherapy respectively.
  • One died of septic complications and one because of a perforated intestine, which had been infiltrated by lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoproliferative Disorders / drug therapy. Organ Transplantation
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Etoposide / administration & dosage. Feasibility Studies. Female. Humans. Male. Middle Aged. Pilot Projects. Salvage Therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14632773.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


8. Praveen S, Ho CC, Fadilah S, Sagap I: Clinical Characteristics and Treatment Outcome of Gastrointestinal Non-Hodgkin's Lymphoma. Med J Malaysia; 2010 Jun;65(2):98-100

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical Characteristics and Treatment Outcome of Gastrointestinal Non-Hodgkin's Lymphoma.
  • Primary gastrointestinal (GIT) lymphoma constitutes only 5 - 10% of all gastrointestinal tumours.
  • The optimal therapy for these lymphomas is poorly defined and still controversial.
  • We present our experience in the treatment and outcome of primary GIT lymphomas in UKM Medical Center, Malaysia.
  • A retrospective review of all patients with primary GIT lymphoma from the year 2002 until 2007 was done.
  • Our series has shown that primary GIT lymphoma is a rare disease as it comprises only 6.5% of all lymphomas treated in this institution.
  • The most common histological variant was diffuse large B cell lymphoma (66%).
  • Most (83%) patients with intestinal lymphoma had surgical resection and adjuvant chemotherapy.
  • All patients with gastric lymphomas had chemotherapy alone.
  • [MeSH-major] Lymphoma, Non-Hodgkin. Treatment Outcome
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Lymphoma, Large B-Cell, Diffuse. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23756789.001).
  • [ISSN] 0300-5283
  • [Journal-full-title] The Medical journal of Malaysia
  • [ISO-abbreviation] Med. J. Malaysia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Malaysia
  •  go-up   go-down


9. Babu RD, Damodaran D: Primary malignant intestinal lymphoma. Trop Gastroenterol; 2001 Apr-Jun;22(2):113-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant intestinal lymphoma.
  • BACKGROUND: Primary malignant intestinal lymphoma is an uncommon gut malignancy.
  • METHODS: Our experience of seven patients with a diagnosis of primary intestinal lymphoma over a period of 22 months is presented here.
  • Acute intestinal obstruction was the commonest presentation.
  • The commonest site was the large intestine (42.6%) especially the caecum.
  • Diffuse large cell, high grade tumour were found to be the commonest histological type.
  • Surgery followed by adjuvant chemotherapy gave good results.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Barium Sulfate. Colectomy / methods. Combined Modality Therapy. Endoscopy, Gastrointestinal. Enema. Female. Humans. Image Enhancement / methods. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • Hazardous Substances Data Bank. Barium sulfate .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11552483.001).
  • [ISSN] 0250-636X
  • [Journal-full-title] Tropical gastroenterology : official journal of the Digestive Diseases Foundation
  • [ISO-abbreviation] Trop Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 25BB7EKE2E / Barium Sulfate
  •  go-up   go-down


10. Van Overbeke L, Ectors N, Tack J: What is the role of celiac disease in enteropathy-type intestinal lymphoma? A retrospective study of nine cases. Acta Gastroenterol Belg; 2005 Oct-Dec;68(4):419-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What is the role of celiac disease in enteropathy-type intestinal lymphoma? A retrospective study of nine cases.
  • BACKGROUND AND AIMS: It is generally accepted that enteropathy-type intestinal lymphoma (EATL) arises against a background of gluten enteropathy.
  • We investigate whether patients with this diagnosis had celiac disease or pre-existing celiac disease, based on gliadin and endomysium antibodies, as well as duodenal biopsies, HLA typing and response to gluten-free diet.
  • METHODS AND RESULTS: Retrospective study of patients with the diagnosis of peripheral T cell lymphoma of the intestine between January 1990 and January 2002 at the university hospital Gasthuisberg Leuven (n = 14).
  • Of the six patients with biopsies of mucosa uninvolved by lymphoma, all of them had villous atrophy; five had increased intraepithelial lymphocytes (IEL).
  • Of the six other patients, one patient never started GFD, two didn't get better, one initially went better after GFD, and one went better with the concomitantly started chemotherapy.
  • [MeSH-major] Celiac Disease / pathology. Cell Transformation, Neoplastic / pathology. Lymphoma, T-Cell / pathology. Precancerous Conditions / pathology

  • Genetic Alliance. consumer health - Celiac Disease.
  • MedlinePlus Health Information. consumer health - Celiac Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16432993.001).
  • [ISSN] 1784-3227
  • [Journal-full-title] Acta gastro-enterologica Belgica
  • [ISO-abbreviation] Acta Gastroenterol. Belg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Autoantibodies
  •  go-up   go-down


11. Tamura H, Ogata K, Kondo A, Wakita T, Inami M, Mizuki T, Hyodo H, Shioi Y, Nakamura K, Mitsui K, Tanaka S, Sakamoto C, Dan K: [Double balloon endoscopy as a useful tool for the diagnosis and treatment of four cases of primary small intestinal lymphoma]. Rinsho Ketsueki; 2007 Jun;48(6):510-3
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Double balloon endoscopy as a useful tool for the diagnosis and treatment of four cases of primary small intestinal lymphoma].
  • Primary small intestinal lymphoma (PSIL) is a relatively rare form of non-Hodgkin lymphoma, often complicated by bleeding, obstruction, or perforation of the intestine during the clinical course.
  • The initial diagnosis and management of these complications are often difficult in PSIL, because the small intestine is usually inaccessible in routine endoscopy.
  • Recently, total enteroscopy with a double-balloon method, called double balloon endoscopy (DBE), has been developed for the diagnosis and treatment of small intestinal disorders.
  • In these cases, DBE was useful in the diagnosis, decision to perform surgery after assessment of bleeding lesion, and treatment of the intestinal stenosis using enteroscopic balloon dilatation.
  • Combination chemotherapy consisting of anthracycline, cyclophosphamide, vincristine, and prednisolone with rituximab was administered in 3 cases, and all achieved complete remission.
  • More PSIL cases must be analyzed to establish the optimal management of patients with this form of lymphoma.
  • [MeSH-major] Catheterization / methods. Endoscopes, Gastrointestinal. Endoscopy, Gastrointestinal / methods. Intestinal Neoplasms / diagnosis. Intestinal Neoplasms / therapy. Intestine, Small. Lymphoma / diagnosis. Lymphoma / therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Fatal Outcome. Female. Humans. Male. Middle Aged. Prednisolone / administration & dosage. Rituximab. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633101.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


12. Huang GT, Zhu GH: [Experience of the diagnosis and treatment of primary small intestine lymphoma]. Zhonghua Wai Ke Za Zhi; 2010 Jan 1;48(1):45-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Experience of the diagnosis and treatment of primary small intestine lymphoma].
  • OBJECTIVE: To report the experiences of the diagnosis and treatment of primary lymphoma of the small intestine (PSIL).
  • Data of gender, age, clinical manifestation, laboratory examination, imageology examination, diagnosis and treatment of the patients was reviewed.
  • All the patients were diagnosed as non-Hodgkin lymphoma (NHL) by postoperative pathology (8 patients as diffuse large B-cell lymphoma, 5 as mucosa associated lymphoid tissue type B cell lymphoma and 2 as enteropathy-type intestinal T cell lymphoma).
  • Ten patients received adjuvant chemotherapy with the regimen of CHOP (cyclophosphamide + epirubicin + vincristine + prednisone) after the operation.
  • Fourteen cases were followed-up for a mean time of 30 months (range, 6 - 52 months).
  • Operation combined with chemotherapy is important for PSIL.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Intestinal Neoplasms / therapy. Intestine, Small / pathology. Lymphoma / diagnosis. Lymphoma / therapy

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20302754.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


13. Daum S, Ullrich R, Heise W, Dederke B, Foss HD, Stein H, Thiel E, Zeitz M, Riecken EO: Intestinal non-Hodgkin's lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal non-Hodgkin's Lymphoma. J Clin Oncol; 2003 Jul 15;21(14):2740-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal non-Hodgkin's lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal non-Hodgkin's Lymphoma.
  • PURPOSE: Intestinal non-Hodgkin's lymphomas are not well characterized.
  • We therefore studied prospectively their clinical features and response to standardized therapy.
  • PATIENTS AND METHODS: Fifty-six patients with primary intestinal lymphoma were included in a prospective, nonrandomized multicenter study.
  • Lymphoma resection was recommended and staging was performed according to the Ann Arbor classification.
  • Patients were scheduled to receive six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) chemotherapy, and at stages EIII to EIV, they received additional involved-field radiotherapy.
  • Corticosteroids were used in patients who could not receive chemotherapy.
  • RESULTS: Thirty-five patients had intestinal T-cell lymphoma (ITCL), 21 patients had intestinal B-cell lymphoma (IBCL; 18 diffuse large-cell lymphomas, two marginal-cell lymphomas, and one follicle-center lymphoma).
  • Thirty-four patients at stages EI to EII (14 ITCL and 20 IBCL) and nine patients at stages EIII to EIV (all ITCL) received chemotherapy.
  • IBCL patients compared with ITCL patients were at lower lymphoma stages (P <.01), had higher Karnofsky status (P <.005), had intestinal perforation less often (P <.05), required emergency operation less often (P <.05), received CHOP (P <.05) more often, and reached complete remission (P <.0005) more frequently.
  • CONCLUSION: IBCL patients at stages EI and EII respond well to chemotherapy, but the prognosis and treatment of ITCL patients is unsatisfactory.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Intestinal Neoplasms / therapy. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols. Combined Modality Therapy. Cyclophosphamide. Doxorubicin. Female. Follow-Up Studies. Germany. Humans. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / mortality. Lymphoma, B-Cell / therapy. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / mortality. Lymphoma, T-Cell / therapy. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prednisolone. Probability. Proportional Hazards Models. Prospective Studies. Radiotherapy, Adjuvant. Risk Assessment. Sex Distribution. Survival Analysis. Survival Rate. Treatment Outcome. Vincristine

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2004 Jul 1;22(13):2752-3; author reply 2753 [15226349.001]
  • (PMID = 12860953.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


14. Hall CH Jr, Shamma M: Primary intestinal lymphoma complicating Crohn's disease. J Clin Gastroenterol; 2003 Apr;36(4):332-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intestinal lymphoma complicating Crohn's disease.
  • Histology examination of the lesion revealed high-grade B-cell lymphoma of Burkitt's type.
  • He was treated with chemotherapy and has done well in the past 12 months.
  • Review of the literature reveals 30 cases of lymphoma in patients with a history of Crohn's disease.
  • [MeSH-major] Burkitt Lymphoma / pathology. Cecal Neoplasms / pathology. Crohn Disease / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Colonoscopy. Follow-Up Studies. Humans. Immunohistochemistry. Male. Risk Assessment. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Gastroenterol. 2009 Jul;43(6):598-9 [19034040.001]
  • (PMID = 12642741.001).
  • [ISSN] 0192-0790
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 57
  •  go-up   go-down


15. Cortelazzo S, Rossi A, Oldani E, Motta T, Giardini R, Zinzani PL, Zucca E, Gomez H, Ferreri AJ, Pinotti G, Chini C, Devizzi L, Gianni AM, Cavalli F, Barbui T, International Extranodal Lymphoma Study Group (IELSG): The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B-cell and diffuse large B-cell histologies. Br J Haematol; 2002 Jul;118(1):218-28
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B-cell and diffuse large B-cell histologies.
  • We have previously reported on the efficacy of a modified International Prognostic Index (MIPI) in predicting the outcome of patients with primary gastric lymphoma.
  • This prompted the retrospective analysis of a large series of patients with primary intestinal lymphoma (PIL) of both diffuse large B-cell (DLCL) and low-grade (extranodal marginal zone B-cell lymphoma, MZL) histology.
  • Clinical records of 122 patients with localized primary intestinal lymphoma of MZL (n=35) and DLCL (n=87) histology, confirmed by an ad hoc expert panel of pathologists, were reviewed.
  • Forty-nine patients were treated with single therapy, while 72 received combined-modality treatment, which included surgery followed by a short-term chemotherapy.
  • [MeSH-major] Intestinal Neoplasms / therapy. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Regression Analysis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12100151.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


16. Jantchou P, Bonnin V, Aubert D: [Oral corticosteroids are efficient in recurrent intussusception associated with intestinal lymphoid hyperplasia]. Arch Pediatr; 2008 Sep;15(9):1420-2
MedlinePlus Health Information. consumer health - Steroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Oral corticosteroids are efficient in recurrent intussusception associated with intestinal lymphoid hyperplasia].
  • [Transliterated title] Intérêt de la corticothérapie dans l'invagination intestinale aiguë sur hyperplasie nodulaire lymphoïde du grêle (iléite folliculaire).
  • We report a case of recurrent intussusception in a 6-year-old boy associated with Intestinal Lymphoid Hyperplasia (ILH).
  • We conclude that steroids treatment must be considered in recurrent intussusception associated with ILH and no other lead point identified (lymphoma or intestinal malformation) instead of a more radical surgical approach by a ileum resection.
  • [MeSH-major] Giant Lymph Node Hyperplasia / complications. Glucocorticoids / therapeutic use. Intestinal Diseases / complications. Intussusception / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18676125.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Glucocorticoids
  •  go-up   go-down


17. Akcali Z, Ozyilkan O, Moray G, Emiroglu R, Haberal M: Treatment results in renal transplant recipients with non-Hodgkin's lymphoma. Transplant Proc; 2003 Jun;35(4):1404-7
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results in renal transplant recipients with non-Hodgkin's lymphoma.
  • The purpose of this study was to investigate the incidence of non-Hodgkin's lymphoma (NHL), response to treatment, and survival time in renal transplant recipients at our center who developed this form of neoplasia.
  • Complete remission was achieved in eight cases, and five of these individuals were still alive at the time of writing.
  • (1) progressive gastric adenocarcinoma 9 years after being diagnosed with NHL, (2) stage III NHL cured with chemotherapy, but died of infection 2 years after NHL diagnosis, and (3) recurrent intestinal lymphoma, with death during second line chemotherapy.
  • The median time from transplantation to diagnosis of NHL was 66 months.
  • At the time of writing, the median survival time for the eight patients who achieved complete remission was 41.5 months.
  • The study showed that treatment of localized disease (skin or intestinal NHL) with surgery and/or radiotherapy/chemotherapy leads to complete remission and long survival times; however, patients in remission are at risk for other causes of death.
  • [MeSH-major] Kidney Transplantation / statistics & numerical data. Lymphoma, Non-Hodgkin / epidemiology. Postoperative Complications / epidemiology
  • [MeSH-minor] Adult. Cadaver. Female. Humans. Incidence. Living Donors. Male. Middle Aged. Survival Analysis. Time Factors. Tissue Donors. Turkey / epidemiology

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12826172.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Wong MT, Eu KW: Primary colorectal lymphomas. Colorectal Dis; 2006 Sep;8(7):586-91
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients often present delayed with nonspecific symptoms and consequently have advanced disease at the time of diagnosis.
  • Treatment often involves a multimodality approach, combining surgery and chemotherapy, with the use of radiotherapy in selected cases.
  • PATIENTS AND METHODS: We reviewed all cases of primary colorectal lymphoma seen at our institution from 1989 to 1999.
  • Patients were included based on standard diagnostic criteria for primary intestinal lymphoma established by Dawson in 1961.
  • The following clinical information was obtained: age, sex, presentation, site of tumour, operation performed, histology, length of stay, intraoperative complications, adjuvant therapy and duration of follow-up.
  • The type of lymphoma was classified according to the WHO classification system.
  • For staging, a modification of the Ann Arbor system for gastrointestinal lymphoma, proposed by Musshoff, was used.
  • Eleven patients (78.6%) received postoperative chemotherapy, with a regimen that included cyclophosphamide, vincristine, doxorubicin and prednisone.
  • CONCLUSION: Primary colorectal lymphoma is a rare condition.
  • Therapy usually involves resection of the affected colon and regional lymphovascular structures, followed by adjuvant chemotherapy, with a reported 5-year survival of 27-55%.
  • [MeSH-major] Colorectal Neoplasms. Lymphoma

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16919111.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 29
  •  go-up   go-down


19. Li B, Shi YK, He XH, Zou SM, Zhou SY, Dong M, Yang JL, Liu P, Xue LY: Primary non-Hodgkin lymphomas in the small and large intestine: clinicopathological characteristics and management of 40 patients. Int J Hematol; 2008 May;87(4):375-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin lymphomas in the small and large intestine: clinicopathological characteristics and management of 40 patients.
  • To investigate the clinicopathological characteristics and optimal treatment modalities of primary non-Hodgkin lymphoma (NHL) in the small and large intestine.
  • Forty patients with primary NHL in the small and large intestine were studied retrospectively.
  • All cases were reclassified according to the World Health Organization (WHO) classification of lymphoma in 2001.
  • Fourteen patients had primary disease in the small intestine, which were all of B-cell origin with diffuse large B-cell lymphoma (DLBCL) diagnosed in 5 of 14 (35.7%) patients and mucosa-associated lymphoid tissue (MALT) lymphoma in 8 of 14 (57.1%) patients.
  • Twenty-five patients had primary colorectal lymphoma, with B-cell origin accounting for 92.0% and T-cell origin for 8.0% of these patients.
  • Compared with surgery alone, post-operation chemotherapy or chemoradiotherapy can significantly improve DLBCL patients' event-free survival (EFS).
  • However, no post-operation treatment modality can improve OS or EFS for patients with MALT lymphoma.
  • B-cell lymphoma is the most common pathological type of intestinal lymphomas.
  • Chemotherapy-containing treatment modality is an effective way to improve intestinal lymphoma patients' EFS, especially for those with DLBCL subtype.
  • [MeSH-major] Intestinal Neoplasms / pathology. Intestinal Neoplasms / therapy. Intestine, Large / pathology. Intestine, Small / pathology. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Zhonghua Wei Chang Wai Ke Za Zhi. 2006 Nov;9(6):502-5 [17143795.001]
  • [Cites] Histopathology. 2003 Aug;43(2):135-43 [12877728.001]
  • [Cites] Am Surg. 1988 May;54(5):262-6 [3364860.001]
  • [Cites] Med Oncol. 2005;22(1):57-62 [15750197.001]
  • [Cites] Cancer. 1985 Mar 1;55(5):1060-73 [3881161.001]
  • [Cites] Cancer Causes Control. 2005 Sep;16(7):781-7 [16132788.001]
  • [Cites] Gastroenterol Jpn. 1976;11(2):141-7 [789171.001]
  • [Cites] Dig Dis Sci. 2005 Dec;50(12):2243-7 [16416168.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7050-9 [16129843.001]
  • [Cites] Gastroenterology. 2000 Nov;119(5):1191-202 [11054376.001]
  • [Cites] Am J Med. 1991 Jan;90(1):77-84 [1702581.001]
  • [Cites] Cancer. 2003 May 15;97(10):2462-73 [12733145.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3861-73 [11559724.001]
  • [Cites] Rofo. 1983 Mar;138(3):283-7 [6403420.001]
  • [Cites] Eur J Surg. 1997 Nov;163(11):803-13 [9414040.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):44-50 [15213617.001]
  • [Cites] Leuk Lymphoma. 2004 Sep;45(9):1847-52 [15223645.001]
  • [Cites] Br J Cancer. 1993 Apr;67(4):776-82 [8471435.001]
  • [Cites] Gastroenterology. 1994 Apr;106(4):846-58 [8143991.001]
  • [Cites] Isr Med Assoc J. 2006 Dec;8(12):832-5 [17214096.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1208-17 [2670184.001]
  • [Cites] Br J Cancer. 1989 Aug;60(2):244-8 [2765374.001]
  • [Cites] Ann Oncol. 2001 Jan;12(1):53-8 [11249049.001]
  • [Cites] Leuk Lymphoma. 2006 Jul;47(7):1253-9 [16923554.001]
  • [Cites] Acta Oncol. 1988;27(1):51-5 [3284553.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):324-37 [10375089.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2006 Feb;28(2):142-4 [16750023.001]
  • [Cites] Dis Colon Rectum. 2000 Sep;43(9):1277-82 [11005497.001]
  • [Cites] Am J Surg Pathol. 2000 May;24(5):688-93 [10800987.001]
  • [Cites] Med Oncol. 2006;23(2):225-35 [16720923.001]
  • [Cites] Cancer. 2005 Aug 1;104(3):532-40 [15937928.001]
  • [Cites] Cancer. 1978 Aug;42(2):693-707 [354774.001]
  • [Cites] Ann Oncol. 1997 Aug;8(8):727-37 [9332679.001]
  • [Cites] Colorectal Dis. 2006 Sep;8(7):586-91 [16919111.001]
  • [Cites] Cancer. 2000 Jan 15;88(2):286-94 [10640959.001]
  • (PMID = 18409078.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


20. Brichon P, Bertrand Y, Plantaz D: [Burkitt's lymphoma revealed by acute intussusception in children]. Ann Chir; 2001 Sep;126(7):649-53
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Burkitt's lymphoma revealed by acute intussusception in children].
  • [Transliterated title] Lymphome de Burkitt révélé par une invagination intestinale aiguë chez l'enfant.
  • STUDY AIM: Burkitt's lymphomas are rarely revealed by acute intestinal intussusception in children.
  • Abdominal ultrasonography showed intestinal intussusception (n = 8) primitive tumor (n = 2), mesentivic lymph nodes (n = 2) and liver nodes (n = 1).
  • Enema (n = 6) confirmed presence and irreductibility of the intestinal intussusception.
  • The procedure consisted in disinvagination (n = 4) and intestinal resection for ischaemia (n = 2).
  • One patient was not operated on and the diagnosis was performed through ultrasonography guided tumoral puncture.
  • With LMB protocol chemotherapy, a complete remission was observed following the first cure.
  • All the children were alive at the time of this study with a follow-up longer than one year after the complete remission.
  • CONCLUSION: Abdominal sonography is the most efficient examination for the diagnosis of intestinal intussusception and sometimes of the primitive lesion.
  • In the absence of sonographic intestinal impair, thanks to ultrasonography guided tumoral puncture, diagnosis may be made and chemotherapy started.
  • If the lymphoma is not visualized with ultrasonography, an emergency laparotomy is necessary for the diagnosis of the lymphoma and the intestinal resection in case of necessity.
  • Burkitt's lymphoma is very sensible to chemotherapy.
  • [MeSH-major] Burkitt Lymphoma / complications. Intussusception / etiology
  • [MeSH-minor] Acute Disease. Child. Diagnosis, Differential. Female. Humans. Laparotomy. Male. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11676236.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


21. Quintas-Cardama A, Fraga M, Antunez J, Forteza J: Primary extramedullary myeloid tumor of the breast: a case report and review of the literature. Ann Hematol; 2003 Jul;82(7):431-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary extramedullary myeloid tumors (PEMMT) are extramedullary proliferations of myeloid cells occurring in the absence of an antecedent myeloproliferative disorder.
  • They have predilection for the skin, lymph nodes, central nervous system, and small intestine.
  • In addition, we present a new case of PEMMT of the breast who presented with a mass in her right breast mimicking a breast malignancy and was initially misdiagnosed as non-Hodgkin's lymphoma.
  • Treatment with systemic chemotherapy and local radiotherapy rendered a complete remission.
  • PEMMT of the breast is a poorly recognized entity whose diagnosis frequently challenges both the pathologist and the oncologist.
  • Given the small number of patients reported no optimal treatment has been defined, but systemic chemotherapy similar to that given for acute myeloid leukemia with or without local radiotherapy may result in long remissions and avoid the progression to overt acute myeloid leukemia.
  • [MeSH-minor] Adult. Combined Modality Therapy. Diagnosis, Differential. Diagnostic Errors. Female. Humans. Neoplasm Invasiveness. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12768322.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 21
  •  go-up   go-down


22. Koh PK, Horsman JM, Radstone CR, Hancock H, Goepel JR, Hancock BW: Localised extranodal non-Hodgkin's lymphoma of the gastrointestinal tract: Sheffield Lymphoma Group experience (1989-1998). Int J Oncol; 2001 Apr;18(4):743-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localised extranodal non-Hodgkin's lymphoma of the gastrointestinal tract: Sheffield Lymphoma Group experience (1989-1998).
  • Extranodal non-Hodgkin's lymphoma (NHL) of the gastrointestinal tract accounts for about one third of all extranodal NHL.
  • We retrospectively reviewed the clinical and histopathologic records of 71 patients with stage IE and IIE primary gastrointestinal NHL referred to the Sheffield Lymphoma Group (SLG) from 1989 to 1998.
  • The most common primary site was the stomach (45 patients, 63% of all cases), followed by the small intestine (16, 23%) and large intestine (9, 13%).
  • Mucosa-associated lymphoid tissue (MALT) lymphomas were the largest histologic subtype seen (57%), with 87% of these arising from the stomach; next most frequent was the diffuse large B-cell subtype (21% of all cases) most frequently arising from the intestine (60%).
  • For treatment of gastric MALT lymphoma, a combined approach (surgery followed by chemotherapy, antihelicobacter therapy followed by chemotherapy) was favoured (22 cases).
  • Knowledge of the Revised European American Lymphoma classification and the Helicobacter pylori/MALT association has influenced treatment approaches over the 10-year study period.
  • For small intestinal lymphoma, surgery (with or without chemotherapy) gave 5- and 10-year survivals of 60%.
  • Overall survival of patients with primary gastrointestinal lymphoma managed by the SLG is similar to that reported from other large series.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Great Britain. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11251169.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


23. Shukla K, Patel T, Shukla J, Palanki S: Primary gastrointestinal lymphoma--a clinicopathologic study. Indian J Pathol Microbiol; 2007 Apr;50(2):296-9
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastrointestinal lymphoma--a clinicopathologic study.
  • Gastrointestinal tract is the most common site for the development ofextra nodal lymphoma.
  • This study was done to analyze clinical and pathological features as well as the treatment outcome of this disease.
  • Out of 25 cases of primary GI lymphoma, nine cases of gastric lymphoma, nine cases of small intestinal lymphoma and seven cases of large intestinal lymphoma were identified.
  • Diffuse large B-cell type and Burkitt's lymphoma were the most common histologic variants, accounting for equal proportions (36% each).
  • All the patients were treated with either surgery alone or in combination of surgery, chemotherapy and radiotherapy depending on the site, stage and histology.
  • 18 cases of GI lymphoma were evaluable, and out of these, 66.6% (11 cases) attained complete remission with a median follow up time of 12 months.
  • In conclusion, although there are considerable therapeutic controversies, surgery with adjuvant chemotherapy and radiotherapy yield good survival.
  • Clinical and histopathologic characteristics and prognosis of our cases with primary gastrointestinal lymphoma were usually similar to the cases in western countries with some differences in the incidence and histologic subtypes.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Female. Helicobacter Infections / diagnosis. Helicobacter pylori / isolation & purification. Humans. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / therapy. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17883049.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


24. Gan JL, Tang ZJ: [Clinical, endoscopic and pathological features of primary colorectal non-Hodgkin lymphoma: 24 cases report]. Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Nov;9(6):502-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical, endoscopic and pathological features of primary colorectal non-Hodgkin lymphoma: 24 cases report].
  • OBJECTIVE: To investigate the clinical, endoscopic and pathological features in primary colorectal non-Hodgkin lymphoma.
  • METHODS: Twenty-four cases of primary colorectal non-Hodgkin lymphoma were studied retrospectively.
  • The major pathology types were diffuse large B-cell lymphoma (11/24, 45.8%), intestinal T-cell lymphoma (8/24, 33.3%), and mucosa-associated lymphoid tissue lymphoma (MALT) (3/24, 12.5%).
  • Sixteen postoperative patients accepted CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or COP (cyclophosphamide, vincristine, prednisone) chemotherapy, and three patients abandoned treatment.
  • CONCLUSION: The clinical features of primary colorectal non-Hodgkin's lymphoma have no specificity.
  • Diffuse large B-cell lymphoma and intestinal T-cell lymphoma are the main pathological types.
  • Comprehensive treatment of surgery and chemotherapy are effective methods for primary colorectal non-Hodgkin lymphoma.
  • [MeSH-major] Colorectal Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Aged. Biopsy. Endoscopy. Female. Follow-Up Studies. Humans. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / pathology. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17143795.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


25. Rathore MA, Andrabi SI, Mansha M: Adult intussusception--a surgical dilemma. J Ayub Med Coll Abbottabad; 2006 Jul-Sep;18(3):3-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is expected to be found in 1/30,000 of all hospital admissions, 1/1300 of all abdominal operations, 1/30-1/100 of all cases operated for intestinal obstruction and one case of adult intussusception for every 20 childhood ones.
  • One intussusception had a malignancy (lymphoma) as a lead point.
  • One patient was referred for chemotherapy for intestinal lymphoma.
  • The treatment almost always is surgical.

  • MedlinePlus Health Information. consumer health - Small Intestine Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17348303.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


26. Ara C, Coban S, Kayaalp C, Yilmaz S, Kirimlioglu V: Spontaneous intestinal perforation due to non-Hodgkin's lymphoma: evaluation of eight cases. Dig Dis Sci; 2007 Aug;52(8):1752-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous intestinal perforation due to non-Hodgkin's lymphoma: evaluation of eight cases.
  • Primary intestinal lymphoma with spontaneous perforation and after systemic chemotherapy is rare.
  • The present study summarizes retrospectively the outcome of eight free intestinal perforated patients diagnosed with intestinal non-Hodgkin's lymphoma.
  • Two patients had a history of systemic chemotherapy before perforation.
  • Synchronous lymphoma was present in three patients.
  • Intestinal lymphoma might be kept in mind as a cause in free intestinal perforations.
  • Because of the high mortality rate early diagnosis and treatment are important to improve the prognosis of bowel perforation in patients with non-Hodgkin's lymphoma.
  • [MeSH-major] Intestinal Neoplasms / complications. Intestinal Perforation / etiology. Lymphoma, Non-Hodgkin / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] Am J Surg. 1991 May;161(5):570-5 [2031540.001]
  • [Cites] Jpn J Clin Oncol. 2002 Dec;32(12):546-9 [12578905.001]
  • [Cites] Arch Surg. 1990 Feb;125(2):252-6 [2302065.001]
  • [Cites] Am J Emerg Med. 2002 Mar;20(2):136-7 [11880888.001]
  • [Cites] Histopathology. 1988 Mar;12(3):235-52 [3366441.001]
  • [Cites] J Natl Cancer Inst. 1987 Apr;78(4):653-6 [3470541.001]
  • [Cites] Cancer. 1985 Mar 1;55(5):1060-73 [3881161.001]
  • [Cites] Cancer. 1985 Jul 15;56(2):259-61 [4005797.001]
  • [Cites] J Gastroenterol. 2002;37(11):939-46 [12483250.001]
  • [Cites] Surg Clin North Am. 1986 Aug;66(4):779-85 [3738698.001]
  • [Cites] J Clin Gastroenterol. 2003 Oct;37(4):299-302 [14506386.001]
  • [Cites] J Clin Oncol. 1994 Aug;12(8):1673-84 [8040680.001]
  • [Cites] Tumori. 2003 Jan-Feb;89(1):88-90 [12729370.001]
  • [Cites] Pediatr Hematol Oncol. 2004 Dec;21(8):707-10 [15739625.001]
  • [Cites] Surg Today. 2002;32(6):536-40 [12107782.001]
  • [Cites] JAMA. 1962 Oct 6;182:23-9 [13861046.001]
  • [Cites] Gastroenterology. 1994 Apr;106(4):846-58 [8143991.001]
  • [Cites] Nihon Ika Daigaku Zasshi. 1999 Feb;66(1):37-40 [10097589.001]
  • [Cites] Surg Today. 2000;30(11):1030-3 [11110402.001]
  • [Cites] Ann Surg. 1980 May;191(5):593-8 [6989331.001]
  • [Cites] Med Pediatr Oncol. 1999 Apr;32(4):302-3 [10102027.001]
  • [Cites] Cancer. 1992 Jan 15;69(2):572-3 [1728388.001]
  • [Cites] Ulus Travma Derg. 2001 Jan;7(1):74-6 [11705180.001]
  • [Cites] Indian J Gastroenterol. 2004 May-Jun;23(3):110-1 [15250572.001]
  • [Cites] Hepatogastroenterology. 1999 Nov-Dec;46(30):3175-7 [10626181.001]
  • (PMID = 17420936.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 27
  •  go-up   go-down


27. Hsiao HH, Liu TC, Chang CS, Sue YC, Chen TP, Lin SF: Secondary chronic myelogenous leukemia after autologous peripheral blood stem cell transplantation for lymphoma. Int J Hematol; 2001 Jan;73(1):126-8
MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary chronic myelogenous leukemia after autologous peripheral blood stem cell transplantation for lymphoma.
  • A 31-year-old woman was diagnosed with intestinal lymphoma (high-grade mucosa-associated lymphoid tissue lymphoma, stage IIE) in September 1996.
  • Eleven courses of chemotherapy were administered, but the results were poor.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / etiology. Lymphoma, B-Cell, Marginal Zone / therapy. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Female. Humans. Intestinal Neoplasms / pathology. Intestinal Neoplasms / therapy. Transplantation, Autologous / adverse effects

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1978 May;51(5):843-50 [273449.001]
  • [Cites] Blood. 1996 May 1;87(9):3633-9 [8611687.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2208-16 [10498590.001]
  • [Cites] Leuk Res. 1999 Oct;23(10):961-4 [10573143.001]
  • [Cites] Bone Marrow Transplant. 1998 Apr;21 Suppl 2:S61-3 [9630329.001]
  • [Cites] Blood. 1995 Oct 15;86(8):3118-22 [7579406.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2187-92 [7931488.001]
  • [Cites] Blood. 1991 Dec 1;78(11):2969-72 [1954384.001]
  • [Cites] J Cancer Res Clin Oncol. 1998;124(3-4):207-14 [9619748.001]
  • [Cites] Br J Haematol. 1994 May;87(1):193-5 [7947245.001]
  • [Cites] Ann Hematol. 1999 Aug;78(8):341-54 [10460347.001]
  • [Cites] Blood. 1998 Mar 15;91(6):1833-44 [9490664.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1933-40 [9731050.001]
  • (PMID = 11372749.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


28. Brankov O, Dumanov K, Stoilov S, Doĭnova P, Drebov R, Khristozova I: [Non-Hodgkin's primary intestinal lymphoma - a cause of acute abdominal manifestation in children]. Khirurgiia (Sofiia); 2007;(4):10-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-Hodgkin's primary intestinal lymphoma - a cause of acute abdominal manifestation in children].
  • AIM: Lymphomas of the gastrointestinal tract are the most common type of primary extranodal lymphomas, accounting for 5 to 10% of all non-Hodgkin's lymphomas (NHL).
  • PATIENTS AND METHODS: From January 1996 to November 2005, 10 patients with primary intestinal lymphomas were submitted with clinical signs of acute abdomen to the Pediatric surgical department in Sofia.
  • According to histology, 5 patients had Burkitt lymphoma and 5 lymphoblast NHL.
  • Prognosis depends of adequacy of surgical resection and the adjuvant chemotherapy.
  • [MeSH-major] Abdomen, Acute / etiology. Intestinal Neoplasms. Lymphoma, Non-Hodgkin

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18443528.001).
  • [ISSN] 0450-2167
  • [Journal-full-title] Khirurgii︠a︡
  • [ISO-abbreviation] Khirurgiia (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


29. Flieger D, Keller R, May A, Ell C, Fischbach W: Capsule endoscopy in gastrointestinal lymphomas. Endoscopy; 2005 Dec;37(12):1174-80
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND STUDY AIMS: Capsule endoscopy (CE) is a new procedure for small-bowel imaging.
  • The potential contribution of this method to the diagnosis and staging of gastrointestinal lymphomas has not yet been evaluated.
  • The aim of this prospective study was to assess the frequency and morphology of different forms of intestinal pathology in patients with gastrointestinal lymphomas.
  • RESULTS: All seven patients with primary intestinal lymphomas who were examined were found to have pathological findings on CE--four with ulcerations, four with nodes, three with villous atrophy, and one with plaques/white villi.
  • One patient with severe diarrhea was examined three times before and after chemotherapy, and improvement of the lesions was evident, as well as resolution of diarrhea.
  • Twenty patients with gastric lymphoma were examined (16 with low-grade and four with high-grade B cell lymphomas).
  • The small-bowel transit times were 261+/-41 min for intestinal lymphoma, 245+/-62 min for gastric lymphoma, and 224+/-82 min for controls (P>0.05).
  • Five of the 20 patients with gastric lymphoma had pathological findings in the intestine--three with plaques/white villi, two with nodes, and two with villous atrophy.
  • In two patients, subsequent biopsies revealed secondary follicular lymphoma and high-grade lymphoma, respectively.
  • CONCLUSIONS: CE is a valuable diagnostic tool for defining the extent of bowel involvement and assessing the efficacy of treatment in patients with gastrointestinal lymphoma.
  • [MeSH-major] Endoscopes, Gastrointestinal. Endoscopy, Gastrointestinal / methods. Gastrointestinal Neoplasms / diagnosis. Lymphoma / diagnosis. Video Recording

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16329013.001).
  • [ISSN] 0013-726X
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


30. Chen LM, Fan YG, Yiang YT, Chang CC, Lee WH: Enteropathy-associated T-cell lymphoma of the jejunum complicated with intestinal perforation. J Chin Med Assoc; 2003 Apr;66(4):252-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enteropathy-associated T-cell lymphoma of the jejunum complicated with intestinal perforation.
  • Enteropathy-associated T-cell lymphoma (EATL) is a rare, well-documented complication of celiac disease, accounting for less than 1% of the non-Hodgkin's lymphomas.
  • Perforation as the presentation of intestinal lymphoma is rare, and as the presentation of EATL is even rarer.
  • Herein, we report a 56-year-old female with EATL of the jejunum complicated with intestinal perforation.
  • After tumor resection and end-to-end anastomosis of the jejunum, the patient received eight courses of CHOP (cyclophosphamide, adriamycin, oncovin and prednisolone) chemotherapy.
  • Now she has been disease-free for one and half years after the diagnosis.
  • From our experience and that of others, we consider that combination chemotherapy should be helpful for patients with EATL.
  • [MeSH-major] Celiac Disease / complications. Intestinal Perforation / etiology. Jejunal Neoplasms / complications. Lymphoma, T-Cell / complications


31. Brain PH, Barrs VR, Martin P, Baral R, White JD, Beatty JA: Feline cholecystitis and acute neutrophilic cholangitis: clinical findings, bacterial isolates and response to treatment in six cases. J Feline Med Surg; 2006 Apr;8(2):91-103
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feline cholecystitis and acute neutrophilic cholangitis: clinical findings, bacterial isolates and response to treatment in six cases.
  • Concurrent pancreatic or intestinal disease was detected histologically in three cases.
  • Treatment was successful in five cases.
  • One cat with concurrent diffuse epitheliotropic intestinal lymphoma was euthanased.
  • [MeSH-major] Cat Diseases / drug therapy. Cat Diseases / microbiology. Cholangitis / veterinary. Cholecystitis, Acute / veterinary
  • [MeSH-minor] Acute Disease. Animals. Cats. Female. Gram-Negative Bacteria / isolation & purification. Gram-Positive Bacteria / isolation & purification. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16278090.001).
  • [ISSN] 1098-612X
  • [Journal-full-title] Journal of feline medicine and surgery
  • [ISO-abbreviation] J. Feline Med. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


32. Marchetti V, Benetti C, Citi S, Taccini V: Paraneoplastic hypereosinophilia in a dog with intestinal T-cell lymphoma. Vet Clin Pathol; 2005 Sep;34(3):259-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraneoplastic hypereosinophilia in a dog with intestinal T-cell lymphoma.
  • Hypoferremia, hypoferritinemia, and a positive fecal occult blood test supported a diagnosis of iron deficiency anemia secondary to chronic intestinal hemorrhage.
  • Abdominal ultrasound evaluation showed a thickened small intestinal loop, of which representative specimens were obtained during exploratory laparotomy.
  • Histologically, the intestinal wall was infiltrated by a neoplastic population of large, round, lymphoid cells with vesicular chromatin, 1 or more prominent nucleoli, and a high number of mitotic figures.
  • A diagnosis of intestinal T-cell lymphoma was made.
  • Chemotherapy was begun, with 30 mg/m;2 of doxorubicin administered intravenously every 3 weeks.
  • An association between hypereosinophilia and T-cell lymphoma is well established in human patients, in whom production of IL-5 by neoplastic T cells has been demonstrated.
  • Hypereosinophilia has been reported only rarely with intestinal lymphoma in cats and horses, and with T-cell lymphoma in dogs.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16134075.001).
  • [ISSN] 0275-6382
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 80168379AG / Doxorubicin
  •  go-up   go-down


33. Kollmar O, Becker S, Schilling MK, Maurer CA: Intestinal lymphoma perforations as a consequence of highly effective anti-CD20 antibody therapy. Transplantation; 2002 Feb 27;73(4):669-70
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal lymphoma perforations as a consequence of highly effective anti-CD20 antibody therapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD20 / immunology. Antineoplastic Agents / therapeutic use. Intestinal Neoplasms / drug therapy. Intestinal Perforation / chemically induced. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Murine-Derived. Humans. Prednisolone / therapeutic use. Rituximab

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11889454.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down






Advertisement